Prespecified secondary analysis of FOURIER (27,564 patients with atherosclerotic disease): evolocumab vs placebo cut MACE by 11% with BMI <30 (HR 0.89), 14% with BMI 30-<35 (HR 0.86) and 29% with BMI ≥35 (HR 0.71); interaction P=0.025.
Secondary analysisn = 27,564
Kang et al. Obesity-Associated Cardiovascular Risk and Benefit From PCSK9 Inhibition: A Prespecified Analysis From FOURIER